Medical Device News Magazine

Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples. Meridian developed these unique master mixes specifically to overcome the adverse effect of inhibitors present in crude urine samples that can affect the sensitivity of a molecular assay.

Urine is an abundant biofluid used to diagnose urinary tract infections (UTIs) and sexually transmitted diseases (STDs), and manage bladder, ovarian, prostate, and kidney diseases. Urine-based biopsies are non-invasive and enable convenient at-home self-sampling, consequently increasing patient compliance and satisfaction. Urine contains substances (e.g., urea) that can inhibit PCR reactions. As such, expensive and time-consuming extraction steps are often needed. Meridian’s new Air-Dryable™ Direct DNA qPCR Urine and Air-Dryable™ Direct RNA/DNA qPCR Urine mixes remove the need for time-consuming RNA or DNA purification or complex component optimization. These mixes produce faster and more sensitive assays directly from urine. Setting up the assay can be as simple as adding primers and probes. Air-Dryable™ technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures. Meridian’s mixes are ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.

Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development at Meridian Life Science, commented, “Urine can be a rich source of material for testing a wide variety of conditions as it is easily accessible and convenient for patients to provide in comparison to other liquid biopsy material such as blood. Interestingly, we have shown that the Air-Dryable™ Direct qPCR Urine mixes are sensitive enough to detect and distinguish co-infecting arboviruses such as Dengue, Zika, and Chikungunya in urine long after the disappearance of viremia in the blood. The Air-Dryable™ Direct qPCR Urine mixes are ideal for developing point-of-care assays with faster workflows and market-leading performance. Meridian’s Air-Dryable™ technology allows oven-drying on-site, saving manufacturing time and expense while allowing control of the entire workflow.”

Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”